Filing Flows › Rapport Therapeutics (RAPP) › Stock forecast & fair value
Rapport Therapeutics (RAPP) stock forecast and price target
Rapport Therapeutics (RAPP) trades at $24.44. 14 analysts' median price target is $67.00 (+174%), from $50.00 to $91.00.
Rapport Therapeutics' latest quarter
Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RAPP stock?
The median of 14 analysts' 12-month targets is $67.00, +174% from $24.44; the range is $50.00 to $91.00. The average rating is strong buy.
Does Rapport Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is RAPP stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.